Sorafenib-Resistant Hepatocellular Carcinoma Stratified by Phosphorylated ERK Activates PD-1 Immune Checkpoint

Clinical Gastroenterology and Hepatology - United Kingdom
doi 10.1016/j.cgh.2016.09.022
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Prognostic Significance of Pd-L1 and Phosphorylated Erk Expression in T-Cell Lymphoma: Pd-1/Pd-L1 Axis Activates Intracellular Erk Signaling in Tumor Cells

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

PD-1 Checkpoint Blockade in Combination With an mTOR Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell-Intrinsic PD-1

Hepatology
MedicineHepatology
2017English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

Efficacy and Safety of Immune Checkpoint Therapy in Hepatocellular Carcinoma: Meta-Analysis

Hepatoma Research
2019English

Direct Therapeutic Targeting of Immune Checkpoint PD-1 in Pancreatic Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model

International Journal of Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2020English

Cytotoxicity of Sorafenib in Human Hepatocellular Carcinoma Cells

Al-Azhar Journal of Pharmaceutical Sciences
2015English

Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Hepatology
MedicineHepatology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy